tolterodine PR

ApprovedSmall molecule

Pfizer

tolterodine PR is one of 113 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Approved.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obstructive Sleep ApneaActive, not recruiting

MemoryActive, not recruiting

Overactive BladderActive, not recruiting

Obstructive Sleep ApneaApproved

Active, not recruiting

MemoryApproved

Active, not recruiting

Overactive BladderPhase 3

Active, not recruiting

Competition

Competitive Landscape

169 competitors in Memory

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Phase 3

1 2

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Phase 3

2 3

Vivarin

HHikma Pharmaceuticals LLC

Phase 3

1 4

Pneumococcal Vaccine

GSK

Phase 3

3 5

Bupropion XL

GSK

Phase 3

1 6

Nicorette

Pfizer

Phase 2

1 7

Avandia

Alnylam Pharmaceuticals

Phase 2

1 8

Cysteine Hydrochloride

Novartis

Phase 2

1 9

Activella

Eli Lilly

Phase 2

1 10

Atgam

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overactive Bladder5 trials

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Completed· Pfizer logo

Pfizer·Phase 3·NCT00444925·1,712 enrolled

A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00768521·20 enrolled

Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women

Completed· Ferring logo

Ferring·Phase 2·NCT01729819·106 enrolled

Show 2 more trials

Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder

Completed· Pfizer logo

Pfizer·Phase 2·NCT00746681·188 enrolled

A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring

Completed· Pfizer logo

Pfizer·Phase 3·NCT00646880·41 enrolled

Completed·UUniversity of California, San Francisco·Phase 4·NCT02436889·23 enrolled

Obstructive Sleep Apnea1 trial

Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome

Completed·YYuzuncu Yil University·Phase 4·NCT05250245·60 enrolled

1 more indication

Unspecified1 trial

Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).

Completed· Pfizer logo

Pfizer··NCT00795509·374 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for tolterodine PR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tolterodine PR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tolterodine PR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

tolterodine PR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overactive Bladder5 trials

Drug1 trial

Tics1 trial

Memory1 trial

Obstructive Sleep Apnea1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News